Abstract
The new non-peptidic protease inhibitor tipranavir is used boosted with ritonavir in a 500/200 mg bid scheme. Multiple drug interactions are described for both drugs because of their different action in CYP450 3A4 and p-glycoprotein. In this retrospective analysis of 22 patients during therapy with tipranavir/ritonavir (TPV) 500 mg/200 mg bid, we found significantly decreased TPV-trough levels in combination with tenofovir (15.32+/-5.22 microg/ml) in comparison to TPV trough levels without tenofovir (20.21+/-14.87 microg/ml). Therapeutic drug monitoring of TPV is recommended.
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives*
-
Alkynes
-
Anti-HIV Agents / administration & dosage*
-
Anti-HIV Agents / blood*
-
Anti-HIV Agents / pharmacokinetics
-
Antiretroviral Therapy, Highly Active
-
Benzoxazines / administration & dosage
-
Cyclopropanes
-
Drug Interactions
-
Drug Monitoring
-
Enfuvirtide
-
HIV Envelope Protein gp41 / administration & dosage
-
HIV Infections / blood*
-
HIV Infections / drug therapy*
-
Humans
-
Organophosphonates / administration & dosage*
-
Peptide Fragments / administration & dosage
-
Pyridines / administration & dosage*
-
Pyridines / blood*
-
Pyridines / pharmacokinetics
-
Pyrones / administration & dosage*
-
Pyrones / blood*
-
Pyrones / pharmacokinetics
-
Retrospective Studies
-
Ritonavir / administration & dosage*
-
Ritonavir / blood
-
Sulfonamides
-
Tenofovir
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
Cyclopropanes
-
HIV Envelope Protein gp41
-
Organophosphonates
-
Peptide Fragments
-
Pyridines
-
Pyrones
-
Sulfonamides
-
Enfuvirtide
-
Tenofovir
-
Adenine
-
efavirenz
-
Ritonavir
-
tipranavir